This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KRON Kronos Bio (KRON) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Kronos Bio Stock (NASDAQ:KRON) 30 days 90 days 365 days Advanced Chart Get Kronos Bio alerts:Sign Up Key Stats Today's Range$0.87▼$0.8850-Day Range$0.67▼$0.8952-Week Range$0.65▼$1.46Volume54,089 shsAverage Volume370,931 shsMarket Capitalization$53.72 millionP/E RatioN/ADividend YieldN/APrice Target$1.63Consensus RatingHold Company Overview Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. Read More Receive KRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address KRON Stock News Headlines$1.8 billion fund is gobbling up Bay Area biotech 'zombies' for cheapJuly 9, 2025 | msn.comKronos Bio Completes Merger with Concentra BiosciencesJune 20, 2025 | tipranks.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 8 at 2:00 AM | Brownstone Research (Ad)Kronos Bio sends Cambridge lab space back to marketJune 5, 2025 | bizjournals.comKronos Bio Terminates Cambridge Lease AgreementJune 5, 2025 | tipranks.comOrca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial OfficerJune 4, 2025 | finance.yahoo.comKRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRONMay 4, 2025 | businesswire.comConcentra To Acquire Kronos BioMay 3, 2025 | nasdaq.comSee More Headlines KRON Stock Analysis - Frequently Asked Questions How were Kronos Bio's earnings last quarter? Kronos Bio, Inc. (NASDAQ:KRON) issued its earnings results on Tuesday, March, 18th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.13. The company earned $2.27 million during the quarter, compared to analyst estimates of $1 million. Kronos Bio had a negative trailing twelve-month return on equity of 64.22% and a negative net margin of 701.53%. When did Kronos Bio IPO? Kronos Bio (KRON) raised $175 million in an IPO on Friday, October 9th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. What other stocks do shareholders of Kronos Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Taseko Mines (TGB), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD). Company Calendar Last Earnings3/18/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRON CIK1741830 Webkronosbio.com Phone650-781-5200FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Kronos Bio$1.63 High Price Target$2.25 Low Price Target$1.00 Potential Upside/Downside+84.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$86.08 million Net Margins-701.53% Pretax Margin-701.53% Return on Equity-64.22% Return on Assets-47.17% Debt Debt-to-Equity RatioN/A Current Ratio12.93 Quick Ratio12.93 Sales & Book Value Annual Sales$9.85 million Price / Sales5.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book0.61Miscellaneous Outstanding Shares61,050,000Free Float46,155,000Market Cap$53.72 million OptionableOptionable Beta1.64 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:KRON) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.